免疫調節剤市場レポート：2030年までの動向、予測、競合分析

免疫調節剤の動向と予測

世界の免疫調節剤市場は、2024年から2030年までのCAGRが4.6%で、2030年までに推定2億9,800万米ドルに達すると予測されます。この市場の主な促進要因は、多発性硬化症の罹患率の増加、効率的な薬剤に対する患者のニーズの高まり、自己免疫疾患の割合の増加です。世界の免疫調節剤市場の将来は、呼吸器、腫瘍、HIVの各市場における機会によって有望視されています。

セグメント別の免疫調節剤

本調査では、世界の免疫調節剤の製品タイプ別、用途別、地域別の予測を掲載しています。

免疫調節剤市場の洞察

Lucintelの予測では、免疫抑制剤は多くの自己免疫疾患を治療することから、予測期間中に高い成長が見込まれます。

この市場の中では、がん領域が予測期間中に最も高い成長を遂げると予想されます。

北米は、人口の間で慢性疾患の有病率が増加していること、主要企業が同地域に存在することから、予測期間中も最大の地域であり続けるでしょう。

よくある質問

Q1.市場規模は：

A1.世界の免疫調節剤市場は、2030年までに推定2億9,800万米ドルに達すると予想されています。

Q2.市場の成長予測は：

A2.世界の免疫調節剤市場は、2024年から2030年にかけてCAGR 4.6%で成長すると予測されます。

Q3.市場の成長に影響を与える主な促進要因は：

A3.この市場の主な促進要因は、多発性硬化症の罹患率の増加、効率的な薬剤に対する患者のニーズの高まり、自己免疫疾患の割合の増加です。

Q4.市場の主要セグメントは：

A4.免疫調節剤市場の将来は、呼吸器、腫瘍、HIV市場に機会があり、有望です。

Q5.市場の主要企業は：

A5.主な免疫調節剤企業は以下の通り：

• F. Hoffmann-La Roche
• Novartis
• Biogen
• Teva Pharmaceutical Industries
• Amgen
• Bristol-Myers & Squibb Company
• Merck Sharp & Dohme

Q6.今後、最大となる市場セグメントは：

A6.Lucintelの予測では、免疫抑制剤は自己免疫疾患を治療する能力があるため、予測期間中に高い成長が見込まれます。

Q7.市場において、今後5年間に最大になると予想される地域は：

A7.北米は、人口の間で慢性疾患の有病率が増加していること、また同地域に主要企業が存在することから、予測期間中も最大の地域であり続けると思われます。

Q8.レポートのカスタマイズは可能か：

A8.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の免疫調節剤市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の免疫調節剤市場の動向（2018～2023年）と予測（2024～2030年）
• 製品タイプ別の世界の免疫調節剤市場
  • 免疫抑制剤
  • 免疫刺激剤
• 用途別の世界の免疫調節剤市場
  • 呼吸器
  • 腫瘍
  • HIV
  • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界の免疫調節剤市場
• 北米の免疫調節剤市場
• 欧州の免疫調節剤市場
• アジア太平洋地域の免疫調節剤市場
• その他地域の免疫調節剤市場

第5章 競合分析

• 製品ポートフォリオ分析
• 業務統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略分析

• 成長機会分析
• 世界の免疫調節剤市場の新たな動向
• 戦略分析
  • 新製品開発
  • 世界の免疫調節剤市場の生産能力拡大
  • 世界の免疫調節剤市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 主要企業の企業プロファイル

• F. Hoffmann-La Roche
• Novartis
• Biogen
• Teva Pharmaceutical Industries
• Amgen
• Bristol-Myers & Squibb Company
• Merck Sharp & Dohme

Immunomodulator Trends and Forecast

The future of the global immunomodulator market looks promising with opportunities in the respiratory, oncology, and HIV markets. The global immunomodulator market is expected to reach an estimated $298.0 million by 2030 with a CAGR of 4.6% from 2024 to 2030. The major drivers for this market are increasing multiple sclerosis incidence, rising patient need for efficient medications, and growing rates of autoimmune disorders.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Immunomodulator by Segment

The study includes a forecast for the global immunomodulator by product type, application, and region.

Immunomodulator Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

• Immunosuppressants
• Immunostimulants

Immunomodulator Market by Application [Shipment Analysis by Value from 2018 to 2030]:

• Respiratory
• Oncology
• HIV
• Others

Immunomodulator Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Immunomodulator Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies immunomodulator companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the immunomodulator companies profiled in this report include-

• F. Hoffmann-La Roche
• Novartis
• Biogen
• Teva Pharmaceutical Industries
• Amgen
• Bristol-Myers & Squibb Company
• Merck Sharp & Dohme

Immunomodulator Market Insights

Lucintel forecasts that immunosuppressant is expected to witness higher growth over the forecast period due to their ability to cure a number of autoimmune illnesses.

Within this market, oncology is expected to witness the highest growth over the forecast period.

North America will remain the largest region over the forecast period due to increasing prevalence of chronic diseases among population and presence of key players in the region.

Features of the Global Immunomodulator Market

Market Size Estimates: Immunomodulator market size estimation in terms of value ($M).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Immunomodulator market size by product type, application, and region in terms of value ($M).

Regional Analysis: Immunomodulator market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, applications, and regions for the immunomodulator market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the immunomodulator market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the immunomodulator market size?

Answer: The global immunomodulator market is expected to reach an estimated $298.0 million by 2030.

Q2. What is the growth forecast for immunomodulator market?

Answer: The global immunomodulator market is expected to grow with a CAGR of 4.6% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the immunomodulator market?

Answer: The major drivers for this market are increasing multiple sclerosis incidence, rising patient need for efficient medications, and growing rates of autoimmune disorders.

Q4. What are the major segments for immunomodulator market?

Answer: The future of the immunomodulator market looks promising with opportunities in the respiratory, oncology, and HIV markets.

Q5. Who are the key immunomodulator market companies?

Answer: Some of the key immunomodulator companies are as follows:

• F. Hoffmann-La Roche
• Novartis
• Biogen
• Teva Pharmaceutical Industries
• Amgen
• Bristol-Myers & Squibb Company
• Merck Sharp & Dohme

Q6. Which immunomodulator market segment will be the largest in future?

Answer: Lucintel forecasts that immunosuppressant is expected to witness higher growth over the forecast period due to their ability to cure a number of autoimmune illnesses.

Q7. In immunomodulator market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to increasing prevalence of chronic diseases among population and presence of key players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the immunomodulator market by product type (immunosuppressants and immunostimulants), application (respiratory, oncology, HIV, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Immunomodulator Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Immunomodulator Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Immunomodulator Market by Product Type
  • 3.3.1: Immunosuppressants
  • 3.3.2: Immunostimulants
• 3.4: Global Immunomodulator Market by Application
  • 3.4.1: Respiratory
  • 3.4.2: Oncology
  • 3.4.3: HIV
  • 3.4.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Immunomodulator Market by Region
• 4.2: North American Immunomodulator Market
  • 4.2.1: North American Immunomodulator Market by Product Type: Immunosuppressants and Immunostimulants
  • 4.2.2: North American Immunomodulator Market by Application: Respiratory, Oncology, HIV, and Others
• 4.3: European Immunomodulator Market
  • 4.3.1: European Immunomodulator Market by Product Type: Immunosuppressants and Immunostimulants
  • 4.3.2: European Immunomodulator Market by Application: Respiratory, Oncology, HIV, and Others
• 4.4: APAC Immunomodulator Market
  • 4.4.1: APAC Immunomodulator Market by Product Type: Immunosuppressants and Immunostimulants
  • 4.4.2: APAC Immunomodulator Market by Application: Respiratory, Oncology, HIV, and Others
• 4.5: ROW Immunomodulator Market
  • 4.5.1: ROW Immunomodulator Market by Product Type: Immunosuppressants and Immunostimulants
  • 4.5.2: ROW Immunomodulator Market by Application: Respiratory, Oncology, HIV, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Immunomodulator Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Immunomodulator Market by Application
  • 6.1.3: Growth Opportunities for the Global Immunomodulator Market by Region
• 6.2: Emerging Trends in the Global Immunomodulator Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Immunomodulator Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Immunomodulator Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: F. Hoffmann-La Roche
• 7.2: Novartis
• 7.3: Biogen
• 7.4: Teva Pharmaceutical Industries
• 7.5: Amgen
• 7.6: Bristol-Myers & Squibb Company
• 7.7: Merck Sharp & Dohme